Evidence map›Paper›PMID 35796319›Full record

ReviewBiomaterials science2022

Membrane-wrapped nanoparticles for nucleic acid delivery.

Mackenzie A Scully, Eric H Sterin, Emily S Day

Abstract readReview
In one paragraph

Review in Biomaterials science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Membrane-modified lipid nanoparticles for RNA delivery.Molecular therapy. Methods & clinical development · 2025
    Review
  5. Nucleic acid drugs: recent progress and future perspectives.Signal transduction and targeted therapy · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Combination cancer imaging and phototherapy mediated by membrane-wrapped nanoparticles.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2023
    Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mackenzie A ScullyBiomedical Engineering, University of Delaware, Newark, DE 19716, USA. emilyday@udel.edu.ORCID http://orcid.org/0000-0001-6443-4287
Eric H SterinBiomedical Engineering, University of Delaware, Newark, DE 19716, USA. emilyday@udel.edu.ORCID http://orcid.org/0000-0002-4705-5717
Emily S DayBiomedical Engineering, University of Delaware, Newark, DE 19716, USA. emilyday@udel.edu.ORCID http://orcid.org/0000-0002-8707-826X

Funding

Understanding synovial macrophage inflamm-aging within osteoarthritisP20GM139760 · NIGMS · UNIVERSITY OF DELAWARE · PI DAWN M ELLIOTT · 2021 to 2026
$19.1M
Maximizing the delivery and efficacy of miRNA therapeutics through nanocarrier designR35GM119659 · NIGMS · UNIVERSITY OF DELAWARE · PI DAY, EMILY S · 2016 to 2020
$2.0M
NIGMS NIH HHS P20 GM139760NIGMS NIH HHS R35 GM119659
6 · The paper itself

Abstract

There is an unmet need for carriers that can deliver nucleic acids (NAs) to cancer cells and tumors to perpetuate gene regulation and manage disease progression. Membrane-wrapped nanoparticles (NPs) can be loaded with exogenously designed nucleic acid cargoes, such as plasmid deoxyribonucleic acid (pDNA), messenger ribonucleic acid (mRNA), small interfering RNA (siRNA), microRNA (miRNA), and immunostimulatory CpG oligodeoxynucleotides (CpG ODNs), to mitigate challenges presented by NAs' undesirable negative charge, hydrophilicity, and relatively large size. By conjugating or encapsulating NAs within membrane-wrapped NPs, various physiological barriers can be overcome so that NAs experience increased blood circulation half-lives and enhanced accumulation in intended sites. This review discusses the status of membrane-wrapped NPs as NA delivery vehicles and their advancement in gene regulation for cancer management

Indexed as

MicroRNAsNanoparticlesNeoplasmsNucleic AcidsHumansRNA, Small InterferingMicroRNAsNucleic AcidsRNA, Small Interfering

Identifiers

PMID35796319
PMCPMC9486671

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.